¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÉÇ÷°üÁßÀçÇÐȸ The 2nd K-SCI Symposium : 2019-04-13

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѽÉÇ÷°üÁßÀçÇÐȸ The 2nd K-SCI Symposium : 2019-04-13
±³À°ÀÏÀÚ : 2019-04-13
±³À°Àå¼Ò : ¿¬¼¼´ëÇб³ ¹é¾ç´©¸® ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : The 2nd K-SCI Symposium
ÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ
´ã´çÀÚ : Á¤ÀºÇý
¿¬¶ôó : 02-582-8212  
À̸ÞÀÏ : grace@kscvi.org      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í -Àü¹®ÀÇ/°³¿øÀÇ/ÀϹÝÀÇ: 60,000 -ÀüÀÓÀÇ/Àü°øÀÇ: 30,000 -°£È£»ç/ÀÇ·á±â»ç/ÀÇ´ë»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/ÀÓ»óº´¸®»ç/Àǹ«±â·Ï»ç: 20,000 -»ê¾÷ü/±âŸ: 120,000 -´ëÇѽÉÇ÷°üÁßÀçÇÐȸ Á¤È¸¿ø ¹«·á * ÇöÀåµî·Ï¸¸ °¡´ÉÇÕ´Ï´Ù.      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 09:00~09:40 TAVR Case  ÃÖ½ÂÇõ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 09:40~09:52 Balloon Expandable vs. Self-expandable Valve: Considerations before Procedure  ÀÌÁßÈñ(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 09:52~10:04 TAVR for Patients with Inappropriate Access  °í¿µ±¹(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 10:04~10:16 Complications after TAVR: How Can We Detect & Treat?  ¹Ú´ö¿ì(¿ï»êÀÇ´ë) 
Åä·Ð 04-13 ±×·£µåº¼·ë 10:16~10:30 Discussion  () 
È޽Ġ04-13  10:30~10:50 Coffee Break  () 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 10:50~11:30 PMV or Mitral valve case  ÇÑÁÖ¿ë(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 11:30~11:42 PMV: Step by Step  ±èÁß¼±(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 11:42~11:54 Paravalular Leakage  °íÀ±¼®(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 11:54~12:06 Mitral Clip: Clinical Evidence and Technique  ±èÁØÈ«(ºÎ»êÀÇ´ë) 
Åä·Ð 04-13 ±×·£µåº¼·ë 12:06~12:20 Discussion  () 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 12:20~12:50 Edwards SAPIEN 3 : Insurmountable Execellency of Procedural Optimization and Long Term Durability  Àå±âÀ°(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 12:50~13:20 Recent Updates From Evolut R/PRO Technology and Outcomes  È«¸í±â(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 13:20~14:00 LAAO Case  ±èÁß¼±(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 14:00~14:12 Optimal Pre- and Post-procedural Anticoagulation and Antiplatelet Strategy  ¾öÀç¼±(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 14:12~14:24 The Role of LAAO in NOAC Era  ÀÌ¿ÀÇö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 14:24~14:36 LAA Occlusion with ICE  ½Å½Â¿ë(Áß¾ÓÀÇ´ë) 
Åä·Ð 04-13 ±×·£µåº¼·ë 14:36~14:50 Discussion  () 
È޽Ġ04-13  14:50~15:10 Coffee Break  () 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 15:10~15:50 ASD or PFO Case  °­¿õö(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 15:50~16:02 ASD: How to Perform Complicated Cases  Àº¿µ¹Î(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 16:02~16:14 PFO: Neurologist's Perspective  ±è¿µ´ë(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 16:14~16:26 PFO: Cardiologist's Perspective  ¹ÚÀçÇü(°í·ÁÀÇ´ë) 
Åä·Ð 04-13 ±×·£µåº¼·ë 16:26~16:40 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ The 2nd K-SCI Symposium : 2019-04-13""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼­¿ï¼º¸ðº´¿ø ´ëÇѽŰæµÎ°æºÎ¿µ»óÀÇÇÐȸ 2019³â KSNR Á¤±âÇмú´ëȸ ¹× ÃÑȸ 2ÀÏÂ÷ : 2019-04-13
´ÙÀ½±Û °­¸ª¾Æ»êº´¿ø ³úÁ¹Áß¼¾ÅÍ °³¼Ò 2Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2019-04-13
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
422 ¼­¿ï Á߾Ӵ뺴¿ø È£Èí±â¾Ë·¹¸£±â³»°ú ¿¬¼ö°­Á : 2018-09-09 1 804 2018-08-15
421 ¼­¿ï ´ëÇѼºÇü¿Ü°úÇÐȸ Ç׳ëÈ­¼ºÇü¿¬±¸È¸ Á¦4ȸ ½ÉÆ÷Áö¾ö : 2018-09-09 0 820 2018-08-15
420 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦1ȸ ºñ¸¸Àü¹®°¡ ½ÉÈ­°úÁ¤: ºñ¸¸ Àü¹® ÀÎÁ¤ÀÇ ±³À° Part 1. : 2018-09-09 0 582 2018-08-15
419 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø 2018³â Çù·Âº´ÀÇ¿ø ÀÇ»ç ¿¬¼ö°­Á : 2018-09-09 0 1,365 2018-08-15
418 ¼­¿ï Á¦1ȸ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ESD¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2018-09-08 0 868 2018-08-15
417 ¼­¿ï Á¦11ȸ ¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø ÁßȯÀÚÀÇÇÐ ¿¬¼ö°­Á Basic Concepts in Intensive Care, 2018 (BACIC 2018) : 2018-09-08 0 1,382 2018-08-15
416 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ °í·Á´ëÇб³ °í°üÀý ½ÉÆ÷Áö¿ò : 2018-09-08 0 1,107 2018-08-15
415 ¼­¿ï 2018 ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ¿öÅ©¼¥ : 2018-09-08 0 519 2018-08-15
414 ºÎ»ê ´ëÇѼ¼Æ÷º´¸®ÇÐȸ International Session of the 30th Annual Fall Meeting of the Korean Society for Cytopathology : 2018-09-08 0 600 2018-08-15
413 ºÎ»ê 2018³â ºÎ¿ï°æ³»ºÐºñ´ë»çÇÐȸ ´ç´¢º´±³À°ÀÚ ¼¼¹Ì³ª : 2018-09-08 0 1,065 2018-08-15
412 ±¤ÁÖ Àü³²´ëº´¿ø Á¦ 3Â÷ Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç ¿¬¼ö°­Á : 2018-09-08 0 1,091 2018-08-15
411 ºÎ»ê ºÎ»ê´ëº´¿ø 2018³â Á¦1Â÷ ¸ð¹ß¿¬¼ö±³À° (ÁÖÁ¦: Å»¸ðÁõÀÇ Áø´Ü°ú Ä¡·á) : 2018-09-08 0 1,434 2018-08-15
410 °æ±â ¾ÆÁÖ´ëÇб³º´¿ø Á¦6ȸ ¾ÆÁÖ ´ç´¢¹ß ¹× â»ó ½ÉÆ÷Áö¾ö : 2018-09-08 0 1,214 2018-08-15
409 ±¤ÁÖ 2018 Àü³²´ëÇб³º´¿ø ÁßȯÀÚÀÇÇнÉÆ÷Áö¿ò ¹× ±â°èȯ±â¿öÅ©¼ó : 2018-09-08 0 739 2018-08-15
408 ¼­¿ï 2018 ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ¿öÅ©¼¥ : 2018-09-07 0 467 2018-08-15
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷